Identification

Name
Lomefloxacin
Accession Number
DB00978  (APRD01076)
Type
Small Molecule
Groups
Approved, Investigational
Description

Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.

Structure
Thumb
Synonyms
  • (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
  • 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
  • LFLX
  • Lomefloxacine
  • Lomefloxacino
  • Lomefloxacinum
Product Ingredients
IngredientUNIICASInChI Key
Lomefloxacin hydrochloride9VC7S3ZXXB98079-52-8KXEBLAPZMOQCKO-UHFFFAOYSA-N
International/Other Brands
Bareon / Maxaquin
Categories
UNII
L6BR2WJD8V
CAS number
98079-51-7
Weight
Average: 351.3479
Monoisotopic: 351.139447899
Chemical Formula
C17H19F2N3O3
InChI Key
ZEKZLJVOYLTDKK-UHFFFAOYSA-N
InChI
InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)
IUPAC Name
1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12

Pharmacology

Indication

For the treatment of bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: S.pneumoniae, H.influenzae, S.aureus, P.aeruginosa, E. cloacae, P. mirabilis, C. civersus, S. asprphyticus, E.coli, and K.pneumoniae.

Pharmacodynamics

Lomefloxacin is a fluoroquinolone antibiotic used to treat chronic bronchitis, as well as complicated and uncomplicated urinary tract infections. It is also used as a prophylactic or preventative treatment to prevent urinary tract infections in patients undergoing transrectal or transurethral surgical procedures. Flouroquinolones such as lomefloxacin possess excellent activity against gram-negative aerobic bacteria such as E.coli and Neisseria gonorrhoea as well as gram-positive bacteria including S. pneumoniae and Staphylococcus aureus. They also posses effective activity against shigella, salmonella, campylobacter, gonococcal organisms, and multi drug resistant pseudomonas and enterobacter.

Mechanism of action

Lomefloxacin is a bactericidal fluoroquinolone agent with activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of lomefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.

TargetActionsOrganism
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
UDNA topoisomerase 2-alpha
inhibitor
Human
Absorption

Rapid and nearly complete with approximately 95% to 98% of a single oral dose being absorbed.

Volume of distribution
Not Available
Protein binding

10%

Metabolism

Minimally metabolized although 5 metabolites have been identified in human urine. 65% appears as the parent drug in urine and 9% as the glucuronide metabolite.

Route of elimination

The urinary excretion of lomefloxacin was virtually complete within 72 hours after cessation of dosing, with approximately 65% of the dose being recovered as parent drug and 9% as its glucuronide metabolite.

Half life

8 hours

Clearance
  • 271 mL/min/1.73 m2 [creatinine clearance of 110 mL/min/1.73 m2]
  • 31 mL/min/1.73 m2 [creatinine clearance of 0 mL/min/1.73 m2]
Toxicity

Adverse reactions include peripheral neuropathy, nervousness, agitation, anxiety, and phototoxic events (rash, itching, burning) due to sunlight exposure.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the neuroexcitatory activities of Lomefloxacin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Lomefloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Lomefloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Lomefloxacin.Experimental, Illicit
AbirateroneThe serum concentration of Lomefloxacin can be increased when it is combined with Abiraterone.Approved
AcarboseLomefloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Lomefloxacin.Approved, Experimental, Investigational
AcenocoumarolLomefloxacin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Lomefloxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Lomefloxacin.Approved
AlbiglutideLomefloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Lomefloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Lomefloxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Lomefloxacin.Experimental
AlogliptinLomefloxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AluminiumAluminium can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Lomefloxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Lomefloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Lomefloxacin.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Lomefloxacin.Approved, Investigational, Withdrawn
AndrographolideAndrographolide may increase the neuroexcitatory activities of Lomefloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Lomefloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Lomefloxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Lomefloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
ApocyninApocynin may increase the neuroexcitatory activities of Lomefloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Lomefloxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Lomefloxacin.Approved
AzithromycinThe metabolism of Lomefloxacin can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Lomefloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Lomefloxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Lomefloxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Lomefloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
BenzydamineBenzydamine may increase the neuroexcitatory activities of Lomefloxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Lomefloxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Lomefloxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Lomefloxacin.Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BortezomibThe metabolism of Lomefloxacin can be decreased when combined with Bortezomib.Approved, Investigational
BromfenacBromfenac may increase the neuroexcitatory activities of Lomefloxacin.Approved
BromocriptineLomefloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Lomefloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Lomefloxacin.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lomefloxacin.Approved
CaffeineThe metabolism of Lomefloxacin can be decreased when combined with Caffeine.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium levulinate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinLomefloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Lomefloxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Lomefloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Vet Approved
ChlorpropamideLomefloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Lomefloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Lomefloxacin.Approved, Investigational
CitalopramThe metabolism of Lomefloxacin can be decreased when combined with Citalopram.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Lomefloxacin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Lomefloxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Lomefloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Lomefloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Lomefloxacin.Approved
ClorindioneLomefloxacin may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Lomefloxacin can be decreased when combined with Clotrimazole.Approved, Vet Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Lomefloxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Lomefloxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Lomefloxacin.Approved, Investigational
CurcuminCurcumin may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Lomefloxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Lomefloxacin.Experimental
Cyproterone acetateThe serum concentration of Lomefloxacin can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DapagliflozinLomefloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DeferasiroxThe serum concentration of Lomefloxacin can be increased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Lomefloxacin.Approved, Investigational
DelamanidLomefloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Lomefloxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Lomefloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Lomefloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Lomefloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Lomefloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Lomefloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Lomefloxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
DicoumarolLomefloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Lomefloxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Lomefloxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Lomefloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Lomefloxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Lomefloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lomefloxacin.Approved
DiphenadioneLomefloxacin may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideLomefloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomefloxacin.Approved, Investigational
DosulepinThe metabolism of Lomefloxacin can be decreased when combined with Dosulepin.Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
DulaglutideLomefloxacin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuvelisibDuvelisib may increase the neuroexcitatory activities of Lomefloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Lomefloxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Lomefloxacin.Investigational
EmpagliflozinLomefloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Lomefloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Lomefloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Lomefloxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Lomefloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Lomefloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Lomefloxacin.Experimental
Ethyl biscoumacetateLomefloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Lomefloxacin.Investigational, Nutraceutical
ExenatideLomefloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Lomefloxacin.Investigational
FelbinacFelbinac may increase the neuroexcitatory activities of Lomefloxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Lomefloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Lomefloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Lomefloxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Lomefloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric pyrophosphateThe serum concentration of Lomefloxacin can be decreased when it is combined with Ferric pyrophosphate.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Lomefloxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Lomefloxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Lomefloxacin.Approved, Investigational
FluindioneLomefloxacin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Lomefloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Lomefloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Lomefloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Lomefloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Lomefloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Lomefloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Lomefloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Lomefloxacin.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Lomefloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Lomefloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Lomefloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Lomefloxacin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Lomefloxacin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Lomefloxacin.Approved
FluvoxamineThe metabolism of Lomefloxacin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Lomefloxacin.Approved, Investigational, Withdrawn
GitoformateGitoformate may decrease the cardiotoxic activities of Lomefloxacin.Experimental
GliclazideLomefloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideLomefloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideLomefloxacin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideLomefloxacin may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Lomefloxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Lomefloxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Lomefloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Lomefloxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Lomefloxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Lomefloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
Insulin AspartLomefloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirLomefloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineLomefloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineLomefloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanLomefloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproLomefloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Lomefloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Lomefloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Lomefloxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Lomefloxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Lomefloxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Lomefloxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Lomefloxacin.Experimental
Lanthanum carbonateThe serum concentration of Lomefloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LidocaineThe metabolism of Lomefloxacin can be decreased when combined with Lidocaine.Approved, Vet Approved
LiraglutideLomefloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Lomefloxacin.Investigational
LobeglitazoneThe metabolism of Lomefloxacin can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Lomefloxacin.Experimental
LornoxicamLornoxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Lomefloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Lomefloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe serum concentration of Lomefloxacin can be decreased when it is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Lomefloxacin.Investigational
MecaserminLomefloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Lomefloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Lomefloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Withdrawn
MetforminLomefloxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Lomefloxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Lomefloxacin.Experimental
MexiletineThe metabolism of Lomefloxacin can be decreased when combined with Mexiletine.Approved, Investigational
MidostaurinThe metabolism of Lomefloxacin can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneLomefloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolLomefloxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Lomefloxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Lomefloxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lomefloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Lomefloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Lomefloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
NateglinideLomefloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Lomefloxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
NevirapineThe metabolism of Lomefloxacin can be decreased when combined with Nevirapine.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Lomefloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Lomefloxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Lomefloxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Lomefloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Lomefloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Lomefloxacin.Vet Approved
OsimertinibThe serum concentration of Lomefloxacin can be decreased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Lomefloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Lomefloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Lomefloxacin.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomefloxacin.Approved, Vet Approved
PalmidrolPalmidrol may increase the neuroexcitatory activities of Lomefloxacin.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Lomefloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved
ParthenolideParthenolide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Lomefloxacin can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineLomefloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Lomefloxacin.Experimental
PhenindioneLomefloxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonLomefloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Lomefloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lomefloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
PioglitazoneLomefloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Lomefloxacin.Experimental
PramlintideLomefloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Lomefloxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Lomefloxacin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Lomefloxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Lomefloxacin.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Lomefloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Lomefloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Lomefloxacin.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Lomefloxacin can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Lomefloxacin.Experimental
PropacetamolPropacetamol may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Lomefloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Lomefloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Lomefloxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Lomefloxacin.Investigational
QuinaprilQuinapril can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinineLomefloxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideLomefloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Lomefloxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Lomefloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Withdrawn
RopiniroleThe metabolism of Lomefloxacin can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneLomefloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RucaparibThe metabolism of Lomefloxacin can be decreased when combined with Rucaparib.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Lomefloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Lomefloxacin.Approved
SaxagliptinLomefloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Lomefloxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Lomefloxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Lomefloxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SimeprevirThe metabolism of Lomefloxacin can be decreased when combined with Simeprevir.Approved
SitagliptinLomefloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Lomefloxacin.Investigational
Strontium ranelateThe serum concentration of Lomefloxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Lomefloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineLomefloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleLomefloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved
SulfisoxazoleLomefloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
SunitinibLomefloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Lomefloxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Lomefloxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Lomefloxacin.Experimental
Tenofovir disoproxilThe metabolism of Lomefloxacin can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Lomefloxacin.Vet Approved
TeriflunomideThe serum concentration of Lomefloxacin can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Lomefloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
TiclopidineThe metabolism of Lomefloxacin can be decreased when combined with Ticlopidine.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Lomefloxacin.Investigational
TioclomarolLomefloxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Lomefloxacin.Approved, Withdrawn
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Lomefloxacin.Approved, Investigational
TolazamideLomefloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideLomefloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
TolmetinTolmetin may increase the neuroexcitatory activities of Lomefloxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Lomefloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Lomefloxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Lomefloxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Lomefloxacin.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Lomefloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Lomefloxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lomefloxacin.Approved
WarfarinLomefloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Lomefloxacin.Withdrawn
ZucapsaicinThe metabolism of Lomefloxacin can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US4528287
General References
Not Available
External Links
Human Metabolome Database
HMDB0015113
KEGG Drug
D02318
KEGG Compound
C07078
PubChem Compound
3948
PubChem Substance
46508499
ChemSpider
3811
BindingDB
50417952
ChEBI
116278
ChEMBL
CHEMBL561
Therapeutic Targets Database
DAP000653
PharmGKB
PA164749165
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Lomefloxacin
ATC Codes
J01MA07 — LomefloxacinS01AE04 — Lomefloxacin
FDA label
Download (88 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1

Pharmacoeconomics

Manufacturers
  • Pharmacia corp
Packagers
  • GD Searle LLC
  • Unimed Pharmaceuticals Inc.
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)239-240.5 °CPhysProp
water solubility27.2 mg/mLNot Available
logP-0.30TAKACS-NOVAK,K ET AL. (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.106 mg/mLALOGPS
logP0ALOGPS
logP-0.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)5.64ChemAxon
pKa (Strongest Basic)8.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.88 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity90.11 m3·mol-1ChemAxon
Polarizability34.8 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9919
Blood Brain Barrier-0.9856
Caco-2 permeable-0.5416
P-glycoprotein substrateSubstrate0.8953
P-glycoprotein inhibitor INon-inhibitor0.8699
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7933
CYP450 2C9 substrateNon-substrate0.8591
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7284
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.933
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8497
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6283
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7701
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9971 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8282
hERG inhibition (predictor II)Non-inhibitor0.6392
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Benzenoids / Aryl fluorides
show 12 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Tertiary aliphatic/aromatic amine
show 29 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, quinolone antibiotic, fluoroquinolone antibiotic, quinolone, quinolinemonocarboxylic acid (CHEBI:116278)

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Didier ES, Bowers L, Stovall ME, Kuebler D, Mittleider D, Brindley PJ, Didier PJ: Antimicrosporidial activity of (fluoro)quinolones in vitro and in vivo. Folia Parasitol (Praha). 2005 May;52(1-2):173-81. [PubMed:16004377]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Takenouchi T, Ishii C, Sugawara M, Tokue Y, Ohya S: Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother. 1995 Jul;39(7):1414-8. [PubMed:7492077]
  4. Drusano GL, Johnson DE, Rosen M, Standiford HC: Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993 Mar;37(3):483-90. [PubMed:8384815]
  5. Gushchin AE, Ladygina VG, Govorun VM: [Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones]. Mol Gen Mikrobiol Virusol. 1999;(4):19-24. [PubMed:10621934]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Sasabe H, Tsuji A, Sugiyama Y: Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther. 1998 Mar;284(3):1033-9. [PubMed:9495864]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 20:37